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Dear Editors,
Serum levels of the pro-inflammatory cytokines IL-1β,
IL-6 and TNF-α are raised in schizophrenia (Schuld et al.,
2004). However, apart from these pro-inflammatory cyto-
kines, chemokines play an important role in modulating
brain function (Adler and Rogers, 2005). The system of
chemokines and their receptors has been described as a
major regulating system of the brain and the receptor for
CCL2, CCR2, is expressed in the brain by astrocytes,
microglia and neurons (Bajetto et al., 2002). CCL2
(Chemokine (C–C motif) ligand 2) is an important pro-
inflammatory chemokine, playing a key role in the recruit-
ment of monocytes to inflammatory foci (Kamei et al.,
2006; Simeoni et al., 2004). Interestingly, a genotypicFig. 1. a: CCL2 levels are significantly (pb0.026) higher in patients with s
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ism of the CCL2 gene and resistance to anti-psychotic
medication (Mundo et al., 2005) and a predominance of
negative symptoms over positive symptoms (Pae et al.,
2004). TheA-2518Gpolymorphism affects the production
of CCL2 (Mundo et al., 2005). However, it is unclear if
CCL2 serum levels are changed in patients with schizo-
phrenia. One study reported a normal level of CCL2 in the
serum of a small group of institutionalized male patients
(Teixeira et al., 2007), while another study reported an
elevation of CCL2 in the cerebrospinal fluid of a small
group of patients with psychosis serving as controls for a
study on neuro-psychiatric lupus (Iikuni et al., 2006).
Here we present a study on the CCL2 levels in the
serum of 145 patients with chronic schizophrenia. Patients
participated in a study on the prevalence of abnormalities
in glucose metabolism in patients with schizophrenia or
schizo-affective disorder treated with anti-psychotics; the
demographic data, study design, hyperglycemia measure-
ments, diabetes and metabolic syndrome definition and
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tory,medical staff and students, with blood collection at the
same time as the patients. The medical ethics review board
METIGG (Utrecht, The Netherlands) approved the study.
Serum CCL2 levels were measured using the Cy-
tometric Bead Array kit (CBA, BD Biosciences, San
Diego, USA) according to the manufacturer's protocol.
Serum levels of CCL2 were significantly higher in the
145 patients (Fig. 1a, median 196.38 pg/ml, range up
to 955.60 pg/ml) compared to the 105 HC (median
141.41 pg/ml, range up to 310.35 pg/ml, pb0.001).
Because patients and HC differed in age and had
different male/female ratios, data were also analyzed as
randomly selected nested case–controls of 65 cases with
schizophrenia and 65 age and gender-matched HC. This
nested study showed that CCL2 levels were also sig-nificantly higher in patients (Fig. 1a, median 184.67 pg/
ml, range up to 711.82 pg/ml) than in HC (median
151.27 pg/ml, range up to 310.35 pg/ml, pb0.009).
Increased CCL2 levels were independent of the use
of anti-psychotic medication, both regarding the class of
drug (typical versus atypical) as well as regarding the
individual drug. Eleven patients did not use any anti-
psychotic drug for at least three months. The CCL2 level
of this “drug-free” chronic schizophrenic population
was higher than that of the HC (yet numbers were too
small to reach significance). To verify whether the raised
CCL2 level was indeed not due to treatment we retested
the 11 drug-free patients together with 13 newly collected
drug-naive patients (duration of schizophrenia less than
1 year) and 36 age and gender-matched HC for their
CCL2 levels in a separate assay. CCL2 levels were
354 Letter to the Editorsstatistically significantly higher than the HC (patients:
median 302.20 pg/ml, range up to 595.50 pg/ml; HC:
median 154.90 pg/ml, range up to 534.30 pg/ml,
pb0.001).
Serum levels of CCL2 correlated positively
(r=0.152, pb0.05) to the prevalence of the metabolic
syndrome (MS, prevalence in our study population
51/145), defined according to a modified definition
of the National Cholesterol Education Program's
Adult Treatment panel III. And, also it correlated in
particular and negatively (r=−0.108, pb0.052) to the
HDL levels. As a consequence, the levels of CCL2
were significantly higher in patients with MS (Fig. 1a,
median 221.91 pg/ml, range up to 955.60 pg/ml) com-
pared to those without (median 179.08 pg/ml, range up
to 781.80 pg/ml, pb0.026), though it must be noted
that those without MS still had higher serum CCL2
levels compared to the HC population (Fig. 1a, median
141.41 pg/ml, range up to 310.35 pg/ml, pb0.001). It
is tempting to speculate that the extra increased CCL2
levels in schizophrenia patients with the MS reflect a
higher load of atherosclerotic plaques in these patients,
since CCL2 plays a critical role in fatty streak development,
e.g. hypercholesterolemic CCL2 deficient mice have less
arterial lipid deposition (Bajetto et al., 2002).
The CBA allows the simultaneous quantification of
IL-1β, TNF-α and IL-6 in the same test and we found all
three cytokines elevated in the patients (Fig. 1b). These
cytokines did not correlate to the MS and there was no
difference between cytokine levels in patients with or
without the MS. The levels of CCL2 showed a strong
positive correlation to the levels of IL-6, IL-1β and
TNF-α.
Limitation of our study is that outcomes are largely
based on patients with chronic stable schizophrenia with
the vast majority of patients on anti-psychotic medica-
tion while drug-free/naive patients have hardly been
studied. Moreover we were not informed on the
hyperglycemia and the MS in our HC. So, our finding
that CCL2 levels are not due to medication and correlate
at least in part to the presence of MS (and predominantly
to a low HDL-cholesterol) should be taken cautiously
and needs confirmation in a confirmative study using
patients before and after treatment characterized for the
MS and dito HC.References
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